clopidogrel + aspirin + dipyridamole

This entry refers to the antiplatelet regimen evaluated in the RESTART-FR (Antiplatelets after Intracerebral Hemorrhage) clinical trial, sponsored by University Hospital, Lille. The regimen involves the use of one or more antiplatelet agents—specifically clopidogrel, aspirin, or dipyridamole—at the investigator's discretion. The trial is a randomized Phase 3 study investigating whether restarting antiplatelet therapy in patients who survived a spontaneous intracerebral hemorrhage (ICH) while on antithrombotic drugs reduces the risk of recurrent vaso-occlusive disease (serious vascular events) without significantly increasing the risk of recurrent ICH. Clopidogrel is a P2Y12 receptor antagonist that inhibits ADP-induced platelet aggregation. Aspirin is a cyclooxygenase-1 (COX-1) inhibitor that prevents the synthesis of thromboxane A2. Dipyridamole acts as a phosphodiesterase inhibitor and adenosine reuptake inhibitor, increasing intracellular cAMP and cGMP levels to inhibit platelet activation. All three agents are standard-of-care small molecules used for secondary prevention of cardiovascular and cerebrovascular events.

Brand names

PersantineAggrenox

Other names

clopidogrel + aspirin + dypyridamole-University Hospital, Lille-vaso-occlusive diseaseclopidogrel + aspirin + dipyridamoleAntiplatelet therapy